Get the latest cancer news and research. Sort by cancer type or read the current headlines to learn what’s happening in the science of cancer detection and treatment, as well as healthy living tips for dealing with cancer.
24
PharmaGap Inc. is pleased to announce results from the initial testing of its lead cancer drug GAP-107B8 by the U.S. National Cancer Institute (NCI).
20
Results were presented at the 13th World Conference on Lung Cancer in San Francisco. The single arm Phase II study evaluated the therapeutic agent EC145 and the molecular imaging agent EC20 in 42 patients with advanced adenocarcinoma of the lung. Forty percent of patients involved in the clinical trial had already failed at least four chemotherapy regimens prior to enrollment in the study.
13
Exiqon announced the nationwide launch of the ArQive Registry, a prospective, observational study designed to strengthen the supporting data for the Oncotech Extreme Drug Resistance (EDR) Assay and to collect data to help develop novel molecular assays (miRNA) within three key tumor types: colon, lung and ovarian.
ImmunoGen, Inc., a biopharmaceutical company that develops targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, announced the presentation of encouraging initial efficacy, safety and tolerability clinical data with its IMGN901 product candidate in the treatment of small-cell lung cancer (SCLC).
Lung Cancer Alliance (LCA) said that bids are now being requested for another $11.8 million of the $20 million lung cancer research project funded through the Department of Defense's Congressionally Directed Medical Research Program (CDMRP).
The world's top lung cancer specialists, medical professionals and researchers are convening this week in San Francisco, CA for the 13th World Conference on Lung Cancer (WCLC), organized by the International Association for the Study of Lung Cancer (IASLC). According to a series of studies presented today at the WCLC, targeted therapies, as first-line treatment, have the potential to slow cancer growth and improve patient outcomes.
Non-small cell lung cancer patients who have progressed on a cetuximab-containing regimen may respond to erlotinib, Fox Chase Cancer Center researchers reported at the annual meeting of the International Association for the Study of Lung Cancer.
Celera Corporation announced the presentation of data replicating its novel mass spectrometry- based approach to identify and validate circulating protein biomarkers that detect non- small cell lung cancer (NSCLC) in an independent cohort of individuals with lung cancer.
10
U.S. scientists have announced two significant advances in lung cancer research. Dr. Glen Weiss of the Translational Genomics Research Institute made both announcements last week in San Francisco during the 13th World Conference on Lung Cancer.
06
In recent years, oncologists have debated whether patients with a certain type of advanced lung cancer would benefit from surgery. Now a major study published in the journal The Lancet has found that surgery after standard chemotherapy and radiation can be an option for patients.
We care about your feedback. Let us know how we can improve your CancerCompass experience.